Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Body composition substudy of the SECOND-LINE study.

Chen S, Zhang Y.

Lancet HIV. 2017 Jun;4(6):e240. doi: 10.1016/S2352-3018(17)30092-9. No abstract available. Erratum in: Lancet HIV. 2017 Jul;4(7):e283.

PMID:
28576611
2.

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.

Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group.

Lancet HIV. 2017 Jan;4(1):e13-e20. doi: 10.1016/S2352-3018(16)30189-8. Epub 2016 Nov 1.

PMID:
27815068
3.

Lipodystrophy and inflammation predict later grip strength in HIV-infected men: the MACS Body Composition substudy.

Crawford KW, Li X, Xu X, Abraham AG, Dobs AS, Margolick JB, Palella FJ, Kingsley LA, Witt MD, Brown TT.

AIDS Res Hum Retroviruses. 2013 Aug;29(8):1138-45. doi: 10.1089/AID.2013.0020. Epub 2013 May 2.

4.

Body composition substudy of the SECOND-LINE study - Author's reply.

Boyd MA; SECOND-LINE Study Group.

Lancet HIV. 2017 Jun;4(6):e240. doi: 10.1016/S2352-3018(17)30093-0. No abstract available.

PMID:
28576610
5.
6.

In search of a practical tool to assess regional body composition.

Lukaski HC.

Am J Clin Nutr. 2008 Oct;88(4):875-6. No abstract available.

PMID:
18842770
7.

Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.

Moyle GJ, Hardy H, Farajallah A, McGrath SJ, Kaplita S, Ward D.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):40-5. doi: 10.1097/QAI.0000000000000383.

PMID:
25296097
8.

The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.

Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O'Hearn M, Reynes J, Arastéh K, Chung J, Rowell L, Guimaraes D, Bertasso A; TORO 1 and TORO 2 Study Groups.

HIV Med. 2011 Jan;12(1):31-9. doi: 10.1111/j.1468-1293.2010.00845.x.

9.

Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.

Moyle GJ, Hardy H, Farajallah A, DeGrosky M, McGrath D.

Clin Drug Investig. 2014 Apr;34(4):287-96. doi: 10.1007/s40261-014-0175-4.

PMID:
24557728
10.

Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.

Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P; Adult Clinical Trials Group 384.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):508-14.

PMID:
17589373
11.

Body composition in prepubertal, HIV-infected children: a comparison of bioelectrical impedance analysis and dual-energy X-ray absorptiometry.

Palchetti CZ, Patin RV, Machado DM, Szejnfeld VL, Succi RC, Oliveira FL.

Nutr Clin Pract. 2013 Apr;28(2):247-52. doi: 10.1177/0884533612471401. Epub 2013 Feb 27.

PMID:
23447408
12.

Dual-energy X-ray absorptiometry body composition in patients with secondary osteoporosis.

Messina C, Monaco CG, Ulivieri FM, Sardanelli F, Sconfienza LM.

Eur J Radiol. 2016 Aug;85(8):1493-8. doi: 10.1016/j.ejrad.2016.03.018. Epub 2016 Mar 22. Review.

PMID:
27048946
13.

Body composition in HIV-infected patients receiving highly active antiretroviral therapy.

Chițu-Tișu CE, Barbu EC, Lazăr M, Bojincă M, Tudor AM, Hristea A, Abagiu AO, Ion DA, Bădărău AI.

Acta Clin Belg. 2017 Feb;72(1):55-62. doi: 10.1080/17843286.2016.1240426. Epub 2016 Oct 11.

PMID:
27724840
14.

Effect of high-dose cholecalciferol (vitamin D3) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial.

Rovner AJ, Stallings VA, Rutstein R, Schall JI, Leonard MB, Zemel BS.

Osteoporos Int. 2017 Jan;28(1):201-209. doi: 10.1007/s00198-016-3826-x. Epub 2016 Nov 11.

PMID:
27837268
15.

The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters.

Martinez E, Visnegarwala F, Grund B, Thomas A, Gibert C, Shlay J, Drummond F, Pearce D, Edwards S, Reiss P, El-Sadr W, Carr A; INSIGHT SMART study group.

AIDS. 2010 Jan 28;24(3):353-63. doi: 10.1097/QAD.0b013e3283333666.

16.

[To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].

Zhou X, Yu W, Li T, Guo F, Lin Q, Shao H, Tian J, Xu Y, Sun P.

Zhonghua Nei Ke Za Zhi. 2014 Aug;53(8):622-5. Chinese.

PMID:
25376824
17.

Segmental BIA: can we measure lipodystrophy? Emerging data reported at the Ninth Annual ANSA Conference.

Williams K, Pujol G.

Surviv News (Atlanta Ga). 2002 Dec-2003 Jan:9. No abstract available.

PMID:
12569881
18.

A validation study of body composition by bioelectrical impedance analysis in human immunodeficiency virus (HIV)-positive and HIV-negative Hispanic men and women.

Forrester JE, Sheehan HM, Joffe TH.

J Am Diet Assoc. 2008 Mar;108(3):534-8. doi: 10.1016/j.jada.2007.12.003.

PMID:
18313436
19.

Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls.

Delpierre C, Bonnet E, Marion-Latard F, Aquilina C, Obadia M, Marchou B, Massip P, Perret B, Bernard J.

J Clin Densitom. 2007 Oct-Dec;10(4):376-80. Epub 2007 Sep 20.

PMID:
17888698
20.

Methods of assessing body shape and composition in HIV-associated lipodystrophy.

Schwenk A.

Curr Opin Infect Dis. 2002 Feb;15(1):9-16. Review.

PMID:
11964900

Supplemental Content

Support Center